Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Eli Lilly and Company
Kedrion S.p.A.
Medical College of Wisconsin
Pfizer
Pfizer
Dana-Farber Cancer Institute
Kelonia Therapeutics, Inc.
Fred Hutchinson Cancer Center
Shenzhen University General Hospital
Taiho Oncology, Inc.
Astex Pharmaceuticals, Inc.
National Heart, Lung, and Blood Institute (NHLBI)
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Anaveon AG
Hellenic Society of Hematology
Masonic Cancer Center, University of Minnesota
Canadian Myeloma Research Group
Celularity Incorporated
National Heart, Lung, and Blood Institute (NHLBI)
Amgen
Hellenic Society of Hematology
Hellenic Society of Hematology
Hellenic Society of Hematology
Novartis
Rigshospitalet, Denmark
National Heart, Lung, and Blood Institute (NHLBI)
University of Rochester
Merck Sharp & Dohme LLC
Bellicum Pharmaceuticals
National Heart, Lung, and Blood Institute (NHLBI)
M.D. Anderson Cancer Center
University of Erlangen-Nürnberg Medical School
Celgene
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
Baylor College of Medicine
National Heart, Lung, and Blood Institute (NHLBI)
Seagen Inc.
Seagen Inc.
Senesco Technologies, Inc.
AVEO Pharmaceuticals, Inc.
Copenhagen University Hospital at Herlev
Infinity Pharmaceuticals, Inc.